Marksans Pharma Limited Share Price & Analysis
₹233.19▼ -2.49%Updated 5 Jun 2026, 05:02 pm IST
LTP
₹233.19
-2.49%
Open
₹—
High
₹244.42
Low
₹230.5
Close
₹233.19
52W High
₹271
52W Low
₹155
Volume
1734K
Lot Size
1
Sector
Healthcare
Market Cap
₹11K Cr
Face Value
₹1
Mid Cap
Price Chart
Fundamentals
P/E
26.2
Sector P/E
48.9
P/B
3.5
EPS
₹7.96
ROE
15.2%
ROCE
18.8%
D/E Ratio
0.11
Div Yield
0.33%
Book Value
₹66.7
+
Strengths
- ✓Strong return on equity (ROE 15.2%)
- ✓Efficient capital deployment (ROCE 18.8%)
- ✓Attractively valued vs sector (P/E 26.2x vs industry 48.9x)
- ✓Low debt relative to equity (D/E 0.1x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,783 | ₹4.3L Cr | 34.4 | 5.12 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,616 | ₹1.7L Cr | 66.1 | 10.48 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,416 | ₹1.5L Cr | 66.4 | 17.81 | 27.6 | 15.4 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,315 | ₹1.2L Cr | 59.5 | 12.62 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,402 | ₹1.1L Cr | 27.3 | 3.29 | 12.4 | 16.6 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,091 | ₹1.1L Cr | 20 | 4.05 | 21.2 | 21.2 | 0.38 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,283 | ₹1.1L Cr | 25.4 | 2.83 | 11.8 | 13.6 | 0.16 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
MARKSANS · as of Mar 2026
Promoters43.87%
FII22.19%▲0.24
DII4.55%▲0.25
Public29.37%▼0.51
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 43.85% | 43.85% | 43.87% | 43.87% | 43.87% | 43.87% |
| FII | 15.55% | 15.57% | 18.59% | 21.31% | 21.95% | 22.19% |
| DII | 4.76% | 5.17% | 3.75% | 4.10% | 4.30% | 4.55% |
| Public | 35.81% | 35.40% | 33.77% | 30.70% | 29.88% | 29.37% |
Corporate Events
To consider and approve Audited Standalone and Consolidated Financial Results and to consider recommendation of dividend if any, for the Financial Year ended March 31, 2026
Dividend25 May 2026
Dividend - Re 0.80 Per Share
Dividend31 Jul 2025
Dividend - Rs 0.60 Per Share
Dividend16 Sept 2024
Dividend - Re 0.50 Per Share
Dividend6 Jun 2023
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹754 Cr ▲4.7% | ₹720 Cr ▲16.1% | ₹620 Cr ▼12.4% | ₹708 Cr ▲3.8% | ₹682 Cr ▲6.2% | ₹642 Cr ▲8.6% | ₹591 Cr ▲5.5% | ₹560 Cr |
| Op. Profit | ₹161 Cr ▲11.8% | ₹144 Cr ▲44.0% | ₹100 Cr ▼21.3% | ₹127 Cr ▼8.6% | ₹139 Cr ▼5.4% | ₹147 Cr ▲14.8% | ₹128 Cr ▲16.4% | ₹110 Cr |
| OPM | 21.0% ▲5.0% | 20.0% ▲25.0% | 16.0% ▼11.1% | 18.0% ▼10.0% | 20.0% ▼13.0% | 23.0% ▲4.5% | 22.0% ▲10.0% | 20.0% |
| Net Profit | ₹114 Cr ▲15.2% | ₹99 Cr ▲70.7% | ₹58 Cr ▼36.3% | ₹91 Cr ▼13.3% | ₹105 Cr ▲7.1% | ₹98 Cr ▲10.1% | ₹89 Cr ▲14.1% | ₹78 Cr |
| EPS (₹) | 2.5 ▲15.2% | 2.17 ▲68.2% | 1.29 ▼35.5% | 2 ▼13.4% | 2.31 ▲8.5% | 2.13 ▲8.7% | 1.96 ▲13.3% | 1.73 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.0K Cr ▲12.5% | ₹2.6K Cr ▲20.5% | ₹2.2K Cr ▲17.5% | ₹1.9K Cr ▲24.2% | ₹1.5K Cr ▲8.4% | ₹1.4K Cr ▲21.3% | ₹1.1K Cr ▲13.4% | ₹1.0K Cr ▲9.5% | ₹913 Cr ▲19.0% | ₹767 Cr |
| Expenses | ₹2.4K Cr ▲12.2% | ₹2.1K Cr ▲21.8% | ₹1.7K Cr ▲13.6% | ₹1.5K Cr ▲22.8% | ₹1.2K Cr ▲18.8% | ₹1.0K Cr ▲10.1% | ₹942 Cr ▲8.5% | ₹868 Cr ▲4.1% | ₹834 Cr ▲15.5% | ₹722 Cr |
| Op. Profit | ₹601 Cr ▲13.6% | ₹529 Cr ▲15.3% | ₹459 Cr ▲35.0% | ₹340 Cr ▲31.3% | ₹259 Cr ▼23.8% | ₹340 Cr ▲77.1% | ₹192 Cr ▲45.5% | ₹132 Cr ▲69.2% | ₹78 Cr ▲73.3% | ₹45 Cr |
| OPM | 20.0% ▲0.0% | 20.0% ▼4.8% | 21.0% ▲16.7% | 18.0% ▲5.9% | 17.0% ▼32.0% | 25.0% ▲47.1% | 17.0% ▲30.8% | 13.0% ▲44.4% | 9.0% ▲50.0% | 6.0% |
| Other Income | ₹83 Cr ▲18.6% | ₹70 Cr ▲40.0% | ₹50 Cr ▼15.3% | ₹59 Cr ▲40.5% | ₹42 Cr ▲500.0% | ₹7 Cr | ₹0 Cr ▼100.0% | ₹5 Cr ▼37.5% | ₹8 Cr ▲14.3% | ₹7 Cr |
| Interest | ₹24 Cr ▲100.0% | ₹12 Cr ▲9.1% | ₹11 Cr ▲22.2% | ₹9 Cr ▲12.5% | ₹8 Cr ▲0.0% | ₹8 Cr ▼11.1% | ₹9 Cr ▼10.0% | ₹10 Cr ▲0.0% | ₹10 Cr ▲42.9% | ₹7 Cr |
| Depreciation | ₹99 Cr ▲19.3% | ₹83 Cr ▲12.2% | ₹74 Cr ▲42.3% | ₹52 Cr ▲15.6% | ₹45 Cr ▲25.0% | ₹36 Cr ▲33.3% | ₹27 Cr ▲17.4% | ₹23 Cr ▼14.8% | ₹27 Cr ▼10.0% | ₹30 Cr |
| PBT | ₹561 Cr ▲11.3% | ₹504 Cr ▲18.9% | ₹424 Cr ▲25.4% | ₹338 Cr ▲36.3% | ₹248 Cr ▼17.9% | ₹302 Cr ▲92.4% | ₹157 Cr ▲51.0% | ₹104 Cr ▲108.0% | ₹50 Cr ▲233.3% | ₹15 Cr |
| Tax % | 25.0% ▲4.2% | 24.0% ▼7.7% | 26.0% ▲23.8% | 21.0% ▼16.0% | 25.0% ▲19.0% | 21.0% ▼8.7% | 23.0% ▲0.0% | 23.0% ▼17.9% | 28.0% ▲16.7% | 24.0% |
| Net Profit | ₹420 Cr ▲9.7% | ₹383 Cr ▲21.6% | ₹315 Cr ▲18.9% | ₹265 Cr ▲41.7% | ₹187 Cr ▼21.8% | ₹239 Cr ▲97.5% | ₹121 Cr ▲51.2% | ₹80 Cr ▲122.2% | ₹36 Cr ▲227.3% | ₹11 Cr |
| EPS (₹) | 9.22 ▲9.8% | 8.4 ▲21.4% | 6.92 ▲17.7% | 5.88 ▲30.4% | 4.51 ▼21.7% | 5.76 ▲95.3% | 2.95 ▲57.8% | 1.87 ▲133.8% | 0.8 ▲263.6% | 0.22 |
| Div Payout | 0.0% ▼100.0% | 10.0% ▲11.1% | 9.0% ▲0.0% | 9.0% ▲50.0% | 6.0% ▲50.0% | 4.0% ▲33.3% | 3.0% ▲0.0% | 3.0% ▼50.0% | 6.0% ▼73.9% | 23.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹45 Cr ▲0.0% | ₹45 Cr ▲0.0% | ₹45 Cr ▲0.0% | ₹45 Cr ▲9.8% | ₹41 Cr ▲0.0% | ₹41 Cr ▲0.0% | ₹41 Cr ▲0.0% | ₹41 Cr ▲0.0% | ₹41 Cr ▲0.0% | ₹41 Cr |
| Reserves | ₹2.6K Cr ▲9.1% | ₹2.4K Cr ▲19.9% | ₹2.0K Cr ▲18.8% | ₹1.7K Cr ▲46.4% | ₹1.2K Cr ▲37.2% | ₹846 Cr ▲42.2% | ₹595 Cr ▲18.5% | ₹502 Cr ▲16.7% | ₹430 Cr ▲9.7% | ₹392 Cr |
| Borrowings | ₹332 Cr ▲3.1% | ₹322 Cr ▲32.0% | ₹244 Cr ▲98.4% | ₹123 Cr ▲10.8% | ₹111 Cr ▲226.5% | ₹34 Cr ▲13.3% | ₹30 Cr ▼70.0% | ₹100 Cr ▼15.3% | ₹118 Cr ▲7.3% | ₹110 Cr |
| Other Liabilities | ₹422 Cr ▼6.4% | ₹451 Cr ▲21.2% | ₹372 Cr ▲15.5% | ₹322 Cr ▼0.3% | ₹323 Cr ▲5.2% | ₹307 Cr ▲30.1% | ₹236 Cr ▲47.5% | ₹160 Cr ▲12.7% | ₹142 Cr ▼32.1% | ₹209 Cr |
| Total Liabilities | ₹3.4K Cr ▲6.2% | ₹3.2K Cr ▲20.9% | ₹2.7K Cr ▲22.4% | ₹2.2K Cr ▲33.9% | ₹1.6K Cr ▲33.2% | ₹1.2K Cr ▲36.1% | ₹902 Cr ▲12.5% | ₹802 Cr ▲9.7% | ₹731 Cr ▼2.8% | ₹752 Cr |
| Assets | ||||||||||
| Fixed Assets | ₹1.1K Cr ▲7.3% | ₹982 Cr ▲26.5% | ₹776 Cr ▲59.7% | ₹486 Cr ▲13.6% | ₹428 Cr ▲38.5% | ₹309 Cr ▲2.0% | ₹303 Cr ▲12.2% | ₹270 Cr ▼3.2% | ₹279 Cr ▲4.5% | ₹267 Cr |
| CWIP | ₹7 Cr ▼74.1% | ₹27 Cr ▲200.0% | ₹9 Cr ▼10.0% | ₹10 Cr ▲233.3% | ₹3 Cr ▼75.0% | ₹12 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹1 Cr ▲0.0% | ₹1 Cr ▼96.3% | ₹27 Cr ▲2600.0% | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹2.4K Cr ▲6.8% | ₹2.2K Cr ▲19.3% | ₹1.9K Cr ▲10.3% | ₹1.7K Cr ▲40.6% | ₹1.2K Cr ▲32.9% | ₹907 Cr ▲51.4% | ₹599 Cr ▲12.4% | ₹533 Cr ▲18.2% | ₹451 Cr ▼6.8% | ₹484 Cr |
| Total Assets | ₹3.4K Cr ▲6.2% | ₹3.2K Cr ▲20.9% | ₹2.7K Cr ▲22.4% | ₹2.2K Cr ▲33.9% | ₹1.6K Cr ▲33.2% | ₹1.2K Cr ▲36.1% | ₹902 Cr ▲12.5% | ₹802 Cr ▲9.7% | ₹731 Cr ▼2.8% | ₹752 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹207 Cr ▼10.0% | ₹230 Cr ▼3.0% | ₹237 Cr ▲139.4% | ₹99 Cr ▼44.7% | ₹179 Cr ▼23.2% | ₹233 Cr ▲763.0% | ₹27 Cr ▼46.0% | ₹50 Cr ▲257.1% | ₹14 Cr ▼54.8% | ₹31 Cr |
| Investing CF | ₹-49 Cr ▲65.2% | ₹-141 Cr ▲45.6% | ₹-259 Cr ▼208.3% | ₹-84 Cr ▼86.7% | ₹-45 Cr ▲25.0% | ₹-60 Cr ▼361.5% | ₹-13 Cr ▲66.7% | ₹-39 Cr ▼85.7% | ₹-21 Cr ▲82.9% | ₹-123 Cr |
| Financing CF | ₹-65 Cr ▲5.8% | ₹-69 Cr ▼134.8% | ₹198 Cr ▲147.5% | ₹80 Cr ▲633.3% | ₹-15 Cr ▲86.8% | ₹-114 Cr ▼442.9% | ₹-21 Cr ▼800.0% | ₹3 Cr ▲200.0% | ₹-3 Cr ▲94.8% | ₹-58 Cr |
| Net Cash Flow | ₹93 Cr ▲342.9% | ₹21 Cr ▼88.1% | ₹176 Cr ▲87.2% | ₹94 Cr ▼20.3% | ₹118 Cr ▲96.7% | ₹60 Cr ▲957.1% | ₹-7 Cr ▼146.7% | ₹15 Cr ▲250.0% | ₹-10 Cr ▲93.3% | ₹-150 Cr |
| Free Cash Flow | ₹35 Cr ▲59.1% | ₹22 Cr ▼88.0% | ₹184 Cr ▲247.2% | ₹53 Cr ▼60.2% | ₹133 Cr ▼23.6% | ₹174 Cr ▲1142.9% | ₹14 Cr ▲27.3% | ₹11 Cr ▲178.6% | ₹-14 Cr ▲86.1% | ₹-101 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75d ▼1.3% | 76d ▼7.3% | 82d ▼15.5% | 97d ▲34.7% | 72d ▼7.7% | 78d ▲21.9% | 64d ▼9.9% | 71d ▼39.8% | 118d ▲32.6% | 89d |
| Inventory Days | 270d ▲24.4% | 217d ▲13.0% | 192d ▼11.1% | 216d ▼12.9% | 248d ▲60.0% | 155d ▼27.9% | 215d ▲41.4% | 152d ▲0.7% | 151d ▲25.8% | 120d |
| Days Payable | 98d ▲4.3% | 94d ▲3.3% | 91d ▼10.8% | 102d ▼1.0% | 103d ▲45.1% | 71d ▼9.0% | 78d ▲44.4% | 54d ▼58.1% | 129d ▲51.8% | 85d |
| Cash Conv. Cycle | 247d ▲24.1% | 199d ▲8.7% | 183d ▼13.3% | 211d ▼2.8% | 217d ▲33.1% | 163d ▼19.3% | 202d ▲19.5% | 169d ▲20.7% | 140d ▲12.9% | 124d |
| Working Capital Days | 142d ▲10.1% | 129d ▲5.7% | 122d ▲0.8% | 121d ▲16.3% | 104d ▲19.5% | 87d ▼10.3% | 97d ▲38.6% | 70d ▼9.1% | 77d ▲30.5% | 59d |
| ROCE | 20.0% ▼4.8% | 21.0% ▼4.5% | 22.0% ▼4.3% | 23.0% ▼39.5% | 38.0% ▲52.0% | 25.0% ▲38.9% | 18.0% ▲80.0% | 10.0% ▲150.0% | 4.0% ▼82.6% | 23.0% |
Source: Screener.in · Lower days = better efficiency
Related Analysis
Frequently Asked Questions
What is Marksans Pharma Limited share price today?▾
Marksans Pharma Limited (MARKSANS) is currently trading at ₹233.19 on NSE, down 2.49% as of the last market session. Prices update daily after market close on MarketNetra.
Is Marksans Pharma Limited available in F&O (Futures & Options)?▾
Yes, Marksans Pharma Limited (MARKSANS) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Marksans Pharma Limited 52-week high and low?▾
Marksans Pharma Limited's 52-week high is ₹271 and the 52-week low is ₹155. The current price of ₹233.19 is 14.0% below the 52W high.
What is Marksans Pharma Limited P/E ratio?▾
Marksans Pharma Limited's current P/E ratio is 26.2. This indicates the market is paying ₹26.2 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Marksans Pharma Limited options?▾
Marksans Pharma Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade MARKSANS options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.